Immunoglobulins Market Report 2025

This Immunoglobulins market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The immunoglobulins market size has grown strongly in recent years. It will grow from $18.85 billion in 2024 to $20.53 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased prevalence of immunodeficiency disorders, growing geriatric population, rising adoption of immunoglobulins in hospitals, favorable government reimbursement plans, increasing prevalence of chronic and autoimmune diseases.

The immunoglobulins market size is expected to see rapid growth in the next few years. It will grow to $31.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing investment for the development of advanced technologies, growing awareness about immunodeficiency therapies, rising preference among physicians for immunodeficiency therapies, increasing number of emerging markets, expansion of applications in sports and fitness. Major trends in the forecast period include development of wearable and smart compression devices, customization of compression therapy solutions, integration of compression therapy in wound care management, emphasis on patient comfort and compliance in compression therapy, collaboration between manufacturers and healthcare providers for improved patient outcomes.

The growth of the immunoglobulins market is being propelled by the increasing geriatric population. This demographic is particularly susceptible to infectious and autoimmune diseases. Immunoglobulin tests are instrumental in assessing the body's ability to generate antibodies for safeguarding against bacteria, viruses, and allergies. For example, a report from the World Health Organization (WHO) in October 2022 revealed that by 2030, one in six individuals globally is projected to be 60 years or older. Additionally, it is estimated that by 2050, the worldwide population of individuals aged 60 or older will reach 2. 1 billion. Consequently, the rising geriatric population is anticipated to drive demand for the immunoglobulins market throughout the forecast period.

The anticipated growth of the immunoglobulins market is further supported by an increase in healthcare expenditure. Healthcare expenditure encompasses the total financial outlay by individuals, organizations, and governments on healthcare-related services, treatments, medications, medical equipment, facilities, and healthcare administration. Elevated investment in the healthcare sector fosters research and development activities in immunoglobulins, potentially leading to the discovery of advanced therapies and augmenting market growth. A report published by the Centers for Medicare & Medicaid Services in March 2022 estimated an average annual increase of 5. 1% in national health spending between 2021 and 2030, reaching nearly $6. 8 trillion. Moreover, Medicare and Medicaid spending is projected to rise at annual rates of 7. 2% and 5. 6%, respectively, during the same period. Consequently, the escalating healthcare expenditure is a driving force behind the growth of the immunoglobulins market.

Major companies in the immunoglobulins market are creating innovative products, such as intravenous immunoglobulins, to cater to larger customer bases, drive sales, and boost revenue. For example, in September 2024, GC Biopharma, a South Korean biotechnology company, launched ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market, aimed at treating primary humoral immunodeficiency (PI) in adults aged 17 and older. This product is now available to patients through specialty pharmacies. The launch is notable as the U.S. is the largest immunoglobulin market globally, valued at around $11.6 billion. GC Biopharma targets $50 million in sales for ALYGLO in its first year, with plans to escalate this to $300 million by 2028. This ambitious growth strategy includes forming partnerships with major U.S. pharmacy benefit managers and specialty pharmacies, which are vital for the effective distribution of immunoglobulin products.

Major companies in the immunoglobulins market are concentrating on strategic partnerships to develop advanced immunoglobulin products. For instance, Biotest, a Germany-based biotechnology company, launched its immunoglobulin product, Yimmugo, in the United States after receiving FDA approval for the treatment of primary immunodeficiencies (PID). This launch is part of a strategic framework established with Kedrion Biopharma for a long-term distribution agreement anticipated to generate over $1 billion in revenue over seven years. The partnership requires Biotest to supply minimum quantities of Yimmugo, with preparations for its market introduction planned for 2025. This collaboration leverages Kedrion's extensive experience in the immunoglobulin market, addressing the needs of around 500,000 PID patients in the U.S. The agreement not only positions Biotest to expand its presence in the growing immunoglobulin market but also improves patient access to essential therapies.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, completed the acquisition of DJS Antibodies Ltd. for an undisclosed amount. This strategic move is expected to enhance AbbVie's existing antibody research efforts, strengthen its immunology portfolio, and establish a significant presence in the bioscience hub of Oxford, UK. The acquisition provides AbbVie with access to the HEPTAD platform, complementing its robust capabilities in biotherapeutics research. Simultaneously, DJS plans to leverage AbbVie's extensive expertise in drug discovery to advance antibody therapeutics and explore novel biological insights, particularly in challenging targets like GPCRs that have proven resistant to biologics-based approaches. DJS Antibodies Ltd. is a UK-based company specializing in antibody therapeutics.

Major companies operating in the immunoglobulins market include Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited.

North America was the largest region in the immunoglobulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Immunoglobulins, also known as antibodies, are glycoproteins produced by plasma cells, a type of white blood cell. These molecules play a crucial role in the immune response by selectively identifying and binding to specific antigens, such as viruses or bacteria, contributing to their elimination from the body.

The primary types of immunoglobulins include IgG, IgA, IgM, IgE, and IgD. Immunoglobulin G (IgG) is particularly significant as it is the main stimulator of humoral immunity in extracellular fluids like blood, lymph, and saliva. Each type of immunoglobulin serves a distinct function in the immune system's defense against various pathogens. These immunoglobulins are administered through different modes of delivery, including intravenous and subcutaneous routes. They find applications in treating conditions such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), and others. The therapeutic use of immunoglobulins helps address deficiencies in the immune system and manage autoimmune disorders, enhancing the body's ability to fight infections and maintain overall health.

The immunoglobulins market research report is one of a series of new reports that provides immunoglobulins market statistics, including immunoglobulins industry global market size, regional shares, competitors with a immunoglobulins market share, detailed immunoglobulins market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. This immunoglobulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.